Pharmaceutical Executive December 26, 2025
Key Takeaways
- Novartis achieved a 12% sales increase and 22% core operating income growth in 2024, marking a strong financial performance.
- Strategic acquisitions of Calypso Biotech and Argo enhance Novartis’ portfolio in autoimmune and cardiovascular therapeutics.
- The company is focused on executing its pipeline, with plans for 15 submission-enabling readouts and over 30 growth-driving assets.
- Novartis continues to expand in China and Japan, emphasizing innovation and addressing unmet medical needs in various therapeutic areas.
Ahead of the healthcare conference in January, Pharmaceutical Executive takes a look back at Novartis’ history at the conference.
While the company will be attending the conference, Novartis has not yet announced its plans for presentations at the 44th Annual JP Morgan Healthcare Conference.
...Today's Sponsors
Today's Sponsor